Drug Profile


Alternative Names: BAY 1351; BAY X 1351; Norasept

Latest Information Update: 02 Jul 1997

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Chiron Corporation
  • Developer Celltech Group; Chiron Corporation
  • Class Anti-TNF monoclonal antibodies
  • Mechanism of Action Immunosuppressants; Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Septic shock

Most Recent Events

  • 02 Jul 1997 Discontinued-I for Septic shock in Japan (IV)
  • 02 Jul 1997 Discontinued-III for Septic shock in France (IV)
  • 02 Jul 1997 Discontinued-III for Septic shock in Germany (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top